Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.

Abstract

Due to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including IDH1/2 and COL2A1. Several molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies in patients with advanced chondrosarcomas. This review summarizes recent basic studies on biomarkers and molecular targets and recent clinical studies on the treatment of chondrosarcomas.

• Authors: Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Hiroyuki Tsuchiya
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 23 Issue 3 (Jan 20 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 35163019 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• COL2A1 protein, human
• Collagen Type II
• Isocitrate Dehydrogenase

Topics

• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor (antagonists & inhibitors, genetics)
• Bone Neoplasms (drug therapy, metabolism, pathology)
• Chondrosarcoma (drug therapy, metabolism, pathology)
• Collagen Type II (antagonists & inhibitors, genetics)
• Humans
• Isocitrate Dehydrogenase (antagonists & inhibitors, genetics)
• Mutation